Tag Archives: SRNE

Sorrento Therapeutics (SRNE) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sorrento Therapeutics (SRNE – Research Report), with a price target of $30. The company’s shares closed on Friday at $2.14, close to its 52-week low

Analysts Are Bullish on These Healthcare Stocks: Sorrento Therapeutics (SRNE), Tocagen Inc (TOCA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sorrento Therapeutics (NASDAQ:SRNE) and Tocagen Inc (NASDAQ:TOCA) with bullish sentiments. Sorrento Therapeutics (SRNE) In a report released today, Ram Selvaraju from H.C.

Sorrento Therapeutics (SRNE) Received its Third Buy in a Row

After H.C. Wainwright and Oppenheimer gave Sorrento Therapeutics (NASDAQ: SRNE) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Andrew D’silva assigned a Buy rating to Sorrento Therapeutics yesterday and set a price

Analysts Offer Insights on Healthcare Companies: Sorrento Therapeutics (NASDAQ: SRNE) and Aptevo Therapeutics Inc (NASDAQ: APVO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sorrento Therapeutics (NASDAQ:SRNE) and Aptevo Therapeutics Inc (NASDAQ:APVO) with bullish sentiments. Sorrento Therapeutics (SRNE) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy

Sorrento Therapeutics (SRNE) Gets a Buy Rating from Oppenheimer

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE), with a price target of $10. The company’s shares closed yesterday at $5.45. Breidenbach observed: “Thursday, Sorrento reported 2Q results and we

H.C. Wainwright Keeps a Buy Rating on Sorrento Therapeutics

In a report issued on June 11, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sorrento Therapeutics (NASDAQ: SRNE), with a price target of $40. The company’s shares opened today at $7.30. Selvaraju noted: “We draw investors’ attention